Zafgen's second try at Prader-Willi syndrome triggers another safety alarm in preclinical tox study
Zafgen’s $ZFGN latest shot at creating the first therapy to treat patients with rare cases of obesity brought on by Prader-Willi syndrome has hit a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
